Abstract:Objective To study the pharmacokinetics and relative bioavailability of sustained-release lovastatin capsules in healthy Beagle dogs and to assess the bioequivalence and performance of the sustained release of the capsules. Methods Following a single dose of 40 mg of the sustained-release lovastatin capsules(test preparation) and conventional lovostatin capsules(reference preparation) administered by gastrogavage to each of the 4 dogs in a randomized crossover design,the plasma levels of the active drugs at different time points thereafter were determined with HPLC and the plasma drug concentration-time curves of these preparations were drawn.The pharmacokinetic parameters as well as the relative bioavailability were calculated. Results The Tmax values of the test preparation and reference preparation were(2.167±0.408) and((3.167)±0.408)h;the C_(max) values were(23.960±6.091) and(14.307±4.319) nmol·L~(-1);and the AUC_(0~t) were(118.647±13.369) and(129.065±14.729) nmol·h·L~(1),respectively.Calculated with AUC and compared with the reference preparation,the relative bioavailability of lovastatin in the test preparation was (110.4±9.6)% in average.The results of variance analysis showed that the differences between the test and reference preparations with respect to periods and preparations were not significant(P0.05).The differences between individual subjects,however,were significant.The 90% confidence interval of AUC_(0~t) of the test praparation was 101.3%～119.5% of that of the reference preparation. Conclusion The sustained-release lovastatin capsules and the conventional lovastatin capsules were shown to be bioequivalent in terms of the degree of absorption.

Bioequivalence and pharmacokinetics characteristics of clozapine sustained release tablets in Beagle dogs

Study on Preparation of Levetiracetam Sodium Extended-release Tablet and It's Pharmacokinetics in Beagle Dogs

Studies on Preparation of Clozapine Floating Sustained Release Capsules and Its Relative Bioavailability after Multiple Doses Administration in Dogs

Pharmacokinetics and Relative Bioavailability of Sustained-Release Alfzosin Hydrochloride Capsules in Healthy Beagle Dogs

Bioequivalence and Pharmacokinetic Characteristics of Lovastatin Sustained Release Tablets in Beagle Dogs

Bioequivalence of two tablet formulations of cefpodoxime proxetil in beagle dogs

Pharmacokinetics of Melatonin Sustained Release Tablets and Common Tablets in Beagle Dogs

Study on the Bioavailability and Pharmacokinetics of Guaiphenesin Sustained Release Tablets in Beagle Dogs

Study on in Vivo Pharmacokinetics and Relative Bioavailability of Cefprozil Dispersible Tablet in Beagle Dogs

Pharmacokinetics and Bioequivalence of Penciclovir Sustained-release Pellets in Beagle Dog

A Study of the Pharmacokinetics and Bioavailability of Sustained-release Lovastatin Capsules in Dogs

Bioequivalence of Levodopa and Benserazide Hydrochloride Capsules in Beagle Dogs

Plasma concentration of sibutramine hydrochloride in beagle dog assayed by LC-MS and study on its pharmacokinetics

A Pharmacokinetic Study on Carteolol Hydrochloride Matrix Sustained-release Pellets in Beagle Dogs

Pharmacokinetics of cetirizine/pseudoephedrine sustained release tablets in Beagle dogs

Bioavailability of Bicalutamide Tablets in Beagle Dogs

Pharmacokinetics and bioequivalence of deferiprone extended-release tablets in Beagle dogs

Pharmacokinetics of Extended-release Tablets of Quetiapine in Beagle Dogs by HPLC-MS/MS Method

Pharmacokinetic behavior and relative bioavailability of propylthiouracil sustained-release tablets vs market tablets in dogs

Study on Pharmacokinetics of Melatonin Orally Disintegrating Tablets and Common Tablets in Beagle Dogs

A Comparison Study of Main Pharmacokinetic Parameters on Pridinol Mesylate Orally Disintegrating Tablets and Conventional Tablets in Beagle Dogs